1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Drugs In Development, 2022, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 9, 1, 2, 49, 14 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 19 and 2 molecules, respectively.
Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Atherosclerosis - Overview
- Atherosclerosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Atherosclerosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Atherosclerosis - Companies Involved in Therapeutics Development
- Atherosclerosis - Drug Profiles
- Atherosclerosis - Dormant Projects
- Atherosclerosis - Discontinued Products
- Atherosclerosis - Product Development Milestones
- Featured News & Press Releases
- May 31, 2022: Amgen announces positive topline phase 2 data for investigational Olpasiran in adults with elevated lipoprotein(a)
- May 22, 2022: Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease
- Apr 05, 2022: NewAmsterdam Pharma doses first patient in phase 2 trial of Obicetrapib in combination with Ezetimibe as an adjunct to high-intensity statin therapy
- Mar 01, 2022: NewAmsterdam Pharma doses first patient in PREVAIL, the cardiovascular outcomes trial of obicetrapib in adults with atherosclerotic cardiovascular disease (ASCVD)
- Feb 14, 2022: New review article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) inhibition’s role in reducing cardiovascular disease risk
- Feb 08, 2022: Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
- Jan 04, 2022: NewAmsterdam Pharma doses first patient in phase 3 BROADWAY trial of obicetrapib in adults with heterozygous familial hypercholesterolemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD)
- Dec 22, 2021: FDA approves Novartis Leqvio (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
- Nov 08, 2021: Leqvio (inclisiran) reduced LDL-C in people who are overweight or obese
- Sep 23, 2021: Verve Therapeutics reports new preclinical data with VERVE-101 demonstrating robust, durable and precise editing of the PCSK9 gene for the treatment of Cardiovascular Disease
- Sep 01, 2021: World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio(inclisiran)
- Aug 30, 2021: Novartis Leqvio (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD
- Jun 15, 2021: Preclinical data from ImmunoPrecise’s drug pipeline to be presented during the BIO International partnering event
- Jun 03, 2021: Afimmune announces positive data with Epeleuton from preclinical atherosclerosis studies
- May 18, 2021: Novo Nordisk’s ziltivekimab shows promise in Phase II CKD trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Atherosclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Products under Development by Universities/Institutes, 2022 (Contd..1)
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Target, 2022 (Contd..2)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Atherosclerosis - Dormant Projects, 2022
- Atherosclerosis - Discontinued Products, 2022
- Atherosclerosis - Discontinued Products, 2022 (Contd..1)
- Atherosclerosis - Discontinued Products, 2022 (Contd..2)
- Number of Products under Development for Atherosclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABIONYX Pharma SA
- Afimmune Biopharma Ltd
- Allysta Pharmaceuticals Inc
- Amgen Inc
- Amytrx Therapeutics Inc
- Annexin Pharmaceuticals AB
- AptaBio Therapeutics Inc
- Artery Therapeutics Inc
- Asdera LLC
- AstraZeneca Plc
- Athera Biotechnologies AB
- Auxagen Inc
- Band Therapeutics LLC
- Boehringer Ingelheim International GmbH
- Cantargia AB
- Celloram Inc
- Centeer BioTherapeutics Ltd Co
- Civi Biopharma Inc
- CohBar Inc
- Corvidane
- CRISPR Therapeutics AG
- Cyclarity Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Drug Farm Inc
- Elgia Therapeutics Inc
- GenKyoTex SA
- Grindeks AS
- HCW Biologics Inc
- Innolife Co Ltd
- Inotrem SA
- Iproteos SL
- Jenrin Discovery Inc
- KineMed Inc
- Kyttaro Ltd
- LipimetiX Development Inc
- Mandos LLC
- Max Biopharma Inc
- MetiMedi Pharmaceuticals Co Ltd
- NewAmsterdam Pharma BV
- Novartis AG
- Novo Nordisk AS
- Omeros Corp
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pharmahungary Group
- PharmGen Science Inc
- Polysan
- PrimeGen Global Inc
- Rebus Holdings Inc
- Regeneron Pharmaceuticals Inc
- Repair Biotechnologies Inc
- Riparian Pharmaceuticals Inc
- Sansho Co Ltd
- Sema4 OpCo Inc
- Serene LLC
- Shanghai Henlius Biotech Inc
- Shin Poong Pharm Co Ltd
- Signablok Inc
- SynAct Pharma AB
- Takeda Pharmaceutical Co Ltd
- Talem Therapeutics Inc
- Tiara Pharmaceuticals Inc
- Valo Health LLC
- Vascular Biogenics Ltd
- Vasocure Therapeutics
- VasoRx Inc
- VasThera Co Ltd
- Vaxil Bio Therapeutics Ltd
- Verve Therapeutics Inc
- XBiotech Inc
- Zehna Therapeutics LLC
